SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is drawing significant investor interest as shareholders speculate on a potential buyout by activist investor Nelson Peltz, who is reportedly exploring financing options to take the company private. This volatility is further amplified by intense short-squeeze chatter, as the community debates the stock's valuation relative to its high short interest and its aggressive international expansion plans.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending due to strong earnings and a major full-year EBITDA guidance hike, which has sparked intense debate among investors over the company's ability to capitalize on elevated global LNG spot prices. While some market participants are focused on the volatility of Middle East geopolitical tensions and their impact on supply chains, others are closely watching institutional moves and betting on the stock's long-term potential as a critical player in global energy infrastructure.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors weigh recent speculative momentum against ongoing financial performance concerns and volatility ahead of upcoming earnings. Community discourse remains sharply divided, with bulls highlighting the company's dual-technology approach and bookings growth while bears continue to scrutinize high cash burn and dilution risks.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is rallying significantly as investors bet on the companys transition to commercial hardware, spurred by the deployment of its Dirac-3 platform and strategic acquisitions. Community sentiment is highly optimistic, with traders closely monitoring high short interest for potential squeeze opportunities and reacting positively to bullish analyst initiations.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

High-Trend International Group is trending as investors digest a massive surge driven by a corporate governance announcement, with the community actively debating whether the move represents a legitimate short squeeze or a volatile pump-and-dump scheme. Discussions remain highly polarized, as traders analyze the stock's low float and high short interest while navigating significant price swings and trading halts.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 Inc. is trending as traders speculate on potential upside from the company's private holdings in high-profile AI and space firms, including SpaceX and Anthropic. Community discussion remains heavily focused on the fund's net asset value, upcoming IPO catalysts, and ongoing debates regarding the validity of indirect share ownership through special purpose vehicles.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea Ltd is seeing heightened market volatility and intense discussion as the stock experiences a significant sell-off, prompting heavy debate among investors about whether this is a long-term value opportunity or a sign of deeper fundamental struggle. The community is actively weighing the company's strong revenue growth and ecosystem expansion against concerns regarding margin pressure, rising credit costs, and aggressive competition.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is currently the focus of investor attention due to a shift in market sentiment following reports that regulators are moving to end costly food delivery price wars, which many investors view as a positive catalyst for long-term margins. Community discourse is highly polarized, with many retail traders actively discussing the stock's long-standing undervaluation and potential for a sustained recovery, while others remain skeptical due to persistent geopolitical tensions and past price volatility.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is facing intense market volatility following a mixed Q1 report where the company posted a surprise loss but raised its full-year revenue guidance. The community is sharply divided, with bulls pointing to robust subscriber growth and long-term potential in the peptide and weight-loss segments, while bears emphasize margin compression and concerns over the company's competitive moat.

Under Armour, Inc. engages in the development, marketing, and distribution of branded performance apparel, footwear, and accessories for men, women, and youth. It operates through the following geographical segments: North America, EMEA, Asia-Pacific, Latin America, and Other. The company was founded by Kevin A. Plank in 1996 and is headquartered in Baltimore, MD.

Under Armour Inc - Ordinary Shares - Class A

Under Armour Inc Class A

Under Armour is trending as investors debate whether the company's valuation represents a deep value turnaround opportunity or a persistent laggard, with heavy discussions focused on significant insider stake increases by Fairfax Financial and a lingering $434 million legal settlement. The community is actively parsing technical chart patterns and debating management's efficacy, with sentiment split between optimism for a potential buyout and frustration over prolonged share price stagnation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up

BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

Sage Therapeutics (SAGE) delivered earnings and revenue surprises of +17.71% and +80.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biogen Gears Up to Report Q2 Earnings: Here's What to Expect

Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.

What Makes Sage Therapeutics (SAGE) a New Buy Stock

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

JPMorgan cut its price target on Sage Therapeutics to $8.5 from $11 based on the recently announced buyout by Supernus Pharmaceuticals, representing an 8.5% downside from the last close.The research firm maintained a 'Neutral' rating on the stock.Last week, Supernus said it would acquire Sage for $8.5 per share in cash, plus a contingent value right (CVR) worth up to $3.5, based on commercial milestones for Zurzuvae, an FDA-approved treatment for postpartum depression co-developed with Biogen.&nbsp;The total transaction value of up to $12 per share reflects a 79% premium to Sage’s last closing price before the announcement.The deal, expected to close in the third quarter of 2025, is intended to expand Supernus’ neuropsychiatry portfolio and&nbsp;could reduce annual costs by up to&nbsp;$200 million.The company also guaranteed a cash payout at closing, excluding value from the CVR, which remains contingent on future sales performance.&nbsp;Several other firms adjusted their price targets in response to the Supernus deal: Piper Sandler lowered its target to $8.50 from $9,&nbsp;while Truist raised its target to $9 from $8&nbsp;and Canaccord increased its target to $8.50 from $8, each maintaining a ‘Hold’ or ‘Neutral’ rating.&nbsp;BofA removed its rating altogether, stating that Sage shares are no longer trading on fundamentals following the acquisition announcement.H.C. Wainwright noted the $22.4 million breakup fee may not be large enough to prevent a competing offer, particularly from Biogen, which already co-commercializes Zurzuvae with Sage in the U.S.In January, Sage Therapeutics’ board&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/biib-stock-gains-onfda-nod-for-leqembi-dosing/chblEfgRYE">unanimously rejected</a> Biogen's unsolicited offer to acquire all outstanding shares for $7.22 per share.&nbsp;The company said the offer “significantly undervalued” Sage and was not in the best interest of shareholders.On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.Shares of Sage Therapeutics closed up 1.9% at $9.3 on Friday. The stock has risen 60.9% so far in 2025.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone and on a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.

Equity

Supernus Pharmaceuticals, Inc. (SUPN) on Monday announced its intent to <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.supernus.com/news-releases/news-release-details/supernus-pharmaceuticals-acquire-sage-therapeutics-strengthening">acquire</a> Sage Therapeutics, Inc. (SAGE) for up to $795 million. SAGE stock traded 34% higher on Monday morning following the announcement.Under the terms of the deal, Supernus intends to acquire Sage for a total consideration of $12 per share in cash, including $8.50 per share payable at closing and a contingent value right (CVR) worth up to $3.50 per share in cash. The CVR is payable upon achieving certain net sales and commercial milestones, the companies said.The total consideration represents a premium of about 79% from SAGE’s closing price of $6.7 on Friday.The transaction is expected to close in the third quarter of 2025 and strengthen Supernus’ neuropsychiatry portfolio with the addition of Zurzuvae, the only oral medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with postpartum depression.Zurzuvae was co-developed by Sage and Biogen, Inc. (BIIB). Through a collaboration agreement with Biogen, Supernus will report collaboration revenue that is 50% of the total net revenue Biogen records for Zurzuvae in the U.S.In 2024 alone, Sage recorded a collaboration revenue of $36.1 million from net sales of Zurzuvae.Jack Khattar, President and CEO of Supernus Pharmaceuticals, said the acquisition augments the company’s growth profile by adding a fourth growth product to its portfolio, in addition to Qelbree, Onapgo, and Gocovri.The acquisition is also expected to be significantly accretive in 2026, with cost synergies of up to $200 million on an annual basis, the companies said.On Stocktwits, retail sentiment around SUPN jumped from ‘neutral’ to ‘bullish territory over the past 24 hours, while chatter increased from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_10_18_03_AM_png_8f57b78080.webp" alt="Screenshot 2025-06-16 at 10.18.03 AM.png" width="625" height="68"><figcaption>SUPN's Sentiment Meter and Message Volume as of 10:15 a.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around SAGE increased from ‘neutral’ to ‘extremely bullish’ territory while message volume increased from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_10_24_57_AM_png_4d871e71b4.webp" alt="Screenshot 2025-06-16 at 10.24.57 AM.png" width="628" height="67"><figcaption>SAGE's Sentiment Meter and Message Volume as of 10:20 a.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure>This year, <a href="https://stocktwits.com/symbol/SAGE">SAGE stock</a> has risen 56% while <a href="https://stocktwits.com/symbol/SUPN">SUPN stock</a> fell about 10%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-organization-enters-telecom-market-touts-us-made-phone/chlntPmRRR8">Trump Organization Enters Telecom Market, Touts US-Made Phone Amid President’s Push To Reshore Smartphone Production</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics

Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.

Why Is Sage Therapeutics (SAGE) Down 11.1% Since Last Earnings Report?

Biogen Inc. shares climbed 1.7% on Monday afternoon, reaching a nearly two-week high, as positive regulatory news countered fallout from a rejected acquisition proposal.Sage Therapeutics announced its board had unanimously rejected Biogen's unsolicited Jan. 10&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sage-stock-soars-on-biogen-bid/chGN0nXRNV">offer</a> to acquire all outstanding Sage shares for $7.22 per share.&nbsp;The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.Sage's board also revealed plans to explore strategic alternatives, cautioning that a transaction is not guaranteed.&nbsp;Meanwhile, Sage reaffirmed its commitment to establishing Zurzuvae as the standard treatment for postpartum depression.&nbsp;Biogen, which co-markets Zurzuvae, had argued that full ownership would aid its rollout but expressed little interest in Sage's broader pipeline when it placed its bid.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BIIB_sentiment_and_message_volume_Jan_27_d1b89b799f.png" alt="BIIB sentiment and message volume Jan 27.png" width="1318" height="324"><figcaption>BIIB sentiment and message volume Jan 27 as of 1:20 pm ET | source: Stocktwits</figcaption></figure>Following the rejection, retail sentiment for Biogen turned 'bearish' on Stocktwits, with increased message volume reflecting investor concerns about the deal's implications.<stembedurl>https://stocktwits.com/Gito/message/601644664</stembedurl><stembedurl>https://stocktwits.com/Scanners_Free/message/601610361</stembedurl>However, Biogen received a significant boost as the FDA on Sunday approved a supplemental biologics license application for Leqembi, developed in collaboration with Eisai Co. Ltd.&nbsp;The new label allows for once-every-four-weeks intravenous maintenance dosing following an 18-month initiation phase of biweekly treatments.Leqembi, used to treat early-stage Alzheimer's disease, addresses patients with mild cognitive impairment or mild dementia.&nbsp;The updated dosing regimen is expected to improve patient compliance while enhancing convenience.However, Biogen's challenges remain stark; the stock has lost nearly 40% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail

The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.

Sage Therapeutics Inc. stock surged over 37% on Monday, reaching its highest level since October, following confirmation of an unsolicited takeover bid from Biogen Inc.&nbsp;The rally sets Sage on track for its&nbsp;most significant percentage gain since Jan. 7, 2019. The stock is also on course to snap a three-day losing streak&nbsp;amidst heavy trading and retail sentiment turning more optimistic.Biogen has offered to acquire the remaining 90% of Sage,&nbsp;which it does not own, for $469 million, or $7.22 per share, representing a premium of over 30% from Sage’s Friday closing price.&nbsp;Sage’s Board of Directors announced they would review the nonbinding proposal carefully to decide the best course of action for the company and its shareholders.The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression.&nbsp;Biogen, which currently shares revenue from Zurzuvae with Sage, argued in an SEC-filed letter that sole ownership would improve the drug’s rollout but notably omitted any interest in Sage’s broader pipeline, according to Barron’s.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SAGE_sentiment_meter_and_message_volume_Jan_13_53ad1877e5.png" alt="SAGE sentiment meter and message volume Jan 13.png" width="1318" height="324"><figcaption>SAGE sentiment meter and message volume Jan 13 as of 2 pm ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned more ‘bullish’ for Sage, with shares surpassing Biogen’s implied offer price, while sentiment for Biogen turned ‘extremely bullish’ as its stock edged higher.<stembedurl>https://stocktwits.com/Dodge2/message/599833394</stembedurl><stembedurl>https://stocktwits.com/Ranger300/message/599788035</stembedurl>Analysts expressed mixed views.&nbsp;Mizuho analyst Uy Ear argued that Biogen’s bid undervalues Sage, suggesting the implied enterprise value is zero, as the company is set to end the fourth quarter with $500 million in net cash.&nbsp;Sage held $569 million in cash and equivalents as of Sep. 30, 2024.The offer also overlooks any valuation for Zurzuvae’s postpartum depression potential or Sage’s early-stage pipeline, including SAGE-319, the analyst added.Meanwhile, Truist analysts noted Zurzuvae’s slow start but predicted a steady launch trajectory, saying “the hardest part of commercialization could be in the rear-view.”Over the past year, Sage’s stock has declined more than 72%, while Biogen shares have dropped nearly 40%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of biopharmaceutical company Sage Therapeutics is seen on a smartphone and on a PC screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In

The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression.

Macy's, Abercrombie and Moderna fall premarket; Sage soars

Investing.com -- US stock futures fell Monday, as investors fretted that the hot jobs report will prompt the Federal Reserve to hold back on rate cuts this year.

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

SAGE
Sage Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest SAGE News

SAGESage Therapeutics Inc